HESTERBIO Hester Bios Q4 FY25 results (Jan–Mar 2025) and concall
Hester Biosciences reported robust profit growth for Q4 and FY25, with standalone profit up 30% and 17% respectively, and consolidated profit up 36% for FY25. This was driven by improved operational efficiency, cost control, and a better product mix, leading to an 8% increase in EBITDA. While overall revenue was flat due to a high base from a prior-year one-time export, underlying divisional product sales grew by 12%. The company is focusing on expanding its Animal Health and Pet Care portfolios and growing its international presence, particularly in Africa, where losses were significantly red
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 |
|---|---|---|---|
| Revenue | 74 | 63 | 77 |
| EBITDA | 15 | 9 | 14 |
| Net profit | 9 | 4 | 10 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
